This Phase I Clinical trial will test the safety, tolerability and pharmacokinetics of Bod’s proprietary Ecs315 extract presented as a sublingual wafer. A positive trial outcome will leave the Company with a unique, patent protected, standardised and reproducible cannabis product which maybe sold or licenced to major pharmaceutical companies.
Perhaps following this trial there should be a 'proof of concept' Phase 1b for a specific condition, possibly targeting the autism spectrum (?) and possibly leading to an IND application with the FDA (?).
